Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Biologics

5

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

3
Last update : 13/12/2013
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Adalimumab
3
Aflibercept
1
Alemtuzumab
1
All-transretinoic acid (ATRA)
4
Anakinra
1
Antiplatelet agents: Glycoprotein IIb/IIIa inhibitors
3
Antithymocyte globulin (ATG-ALG) - Antithymocyte immunoglobulin (ATI)
3
Balsalazide
1
Basiliximab
2
Bevacizumab
3
Bortezomib
2
Certolizumab
1
Cetuximab
4
Crizotinib
4
DMARDs (disease-modifying antirheumatic drugs)
5
Dasatinib
4
Eptifibatide
2
Erlotinib
3
Etanercept
4
Everolimus
5
Fanolesomab-99mTc
1
G/GM-CSF
3
Gefitinib
5
Gemtuzumab
1
Golimumab
1
Imatinib
3
Infliximab
5
Interferon alpha/beta
3
Interferon gamma
1
Interleukin 2 (IL2)
3
Ipilimumab
4
Isotretinoin
1
Lambrolizumab
4
MTOR inhibitors
5
Matuzumab
1
Muromonab-CD3 (OKT3, orthoclone)
1
Natalizumab
1
Nilotinib
2
Nivolumab
5
Omalizumab
2
Palivizumab
1
Panitumumab
1
Pomalidomide
1
Ridaforolimus
2
Rituximab
5
Ruxolitinib
2
Sirolimus
4
Sorafenib
2
Sunitinib
2
TNF-alpha antagonists / inhibitors
5
Temsirolimus
2
Thalidomide
2
Tocilizumab
1
Tofacitinib
2
Tyrosine kinase inhibitors (EGFR) TKI
5
Ustekinumab
1
Vemurafenib
1
Zotarolimus
1

Publications

Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.
Cancer metastasis reviews 2013 Dec;32;723-61 2013 Dec
Managing premedications and the risk for reactions to infusional monoclonal antibody therapy.
The oncologist 2008 Jun;13;725-32 2008 Jun

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies